Risk Factors and Treatment Options for Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer: a Multicentric Retrospective Cohort Study (METABREC)

What this Trial Is About

Researchers are studying brain metastases that occur after esophagectomy, a key surgical treatment for esophageal cancer. This study aims to understand how often brain metastases happen and what risk factors may contribute to them, especially comparing patients who had primary surgery to those who underwent neoadjuvant treatment followed by surgery. The focus is on patients treated between 2000 and 2019, as brain metastases, though rare, can seriously affect survival and treatment options are often challenging. The study involves analyzing medical records of patients who had esophagectomy for esophageal cancer, including those who received various types of neoadjuvant therapies or primary surgery. Researchers will look at factors such as the number, characteristics, and timing of brain metastases, and compare the odds of developing brain metastases between different treatment approaches. This is a retrospective observational study without any new treatment being administered. Participants' data from 2000 to 2019 will be reviewed to determine outcomes like overall survival, time to cancer recurrence, and specific risk factors for brain metastases. The main measurement is the odds ratio for brain metastasis during this period. The study will also assess the number and features of brain metastases. Since this is a retrospective study, there are no visits or procedures for participants, and no direct interventions or follow-up required.

Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)